Pfizer CEO Praises Trump Administration for 'Historic' Drug Pricing Deal

Landmark Drug Pricing Agreement

• 🤝 An historic agreement has been reached between the Trump administration and Pfizer, aiming to reverse an unfair situation where other rich nations did not pay for medical innovation.
• 🇺🇸 Americans have historically borne a disproportionate cost for drug innovation, a situation this new deal seeks to rectify.

Addressing President Trump's Requests

• ✉️ President Trump sent a letter to pharmaceutical companies outlining four specific requests designed to lower drug costs in America.
• ✅ This new deal satisfies all four of those requests, with the primary beneficiary being the American patient.

Benefits for American Innovation and Economy

• 📈 The agreement addresses two major overhangs that have reduced pharmaceutical company valuations: uncertainty of tariffs and drug pricing frameworks.
• 🏭 Pfizer commits to onshoring the production of medicines consumed in the US that are currently made abroad, unleashing investment in the country.
• 💰 A three-year grace period from 232 tariffs is granted as long as production is moved to the US.
• 💡 Clarity on the US pricing framework is now established, removing investment uncertainty for the pharmaceutical industry.
• 🔬 Pfizer plans to invest $70 billion in manufacturing and research in America over the next few years.

Acknowledgements

• 🙏 Pfizer CEO Albert Bourla thanked Secretary Kennedy and Secretary Latnik for their leadership in facilitating the agreement.
• 🌟 He also expressed gratitude to the US trade representative for their engagement and care for the industry.
• 🗣️ The CEO specifically thanked President Trump for his leadership and friendship, highlighting the trust built during negotiations.